Exploration and Study of Jianpi Qushi Powder Combined with Standard Anti HP Quadruple Therapy in the Treatment of HP Infectious Gastritis of Spleen Deficiency and Dampness Stagnation Type
Objective: To explore the
therapeutic effect of traditional Chinese medicine Jianpi Qushi powder combined
with standard anti-HP quadruple therapy in the treatment of HP infectious
gastritis with spleen deficiency and dampness stagnation. Methods: From January
2020 to December 2021, 223 patients with laboratory-confirmed HP infection who
were admitted to the Outpatient and Inpatient Department of Internal Medicine in
our hospital were selected as the research objects and randomly divided into
two groups.101 patients in the control group were given
standard anti HP quadruple therapy; 122 cases in the treatment group were given
traditional Chinese medicine Jianpi Qushi powder combined with standard anti HP
quadruple therapy. The two groups were rechecked carbon breath test after the
designed course of treatment, and the curative effects of the two groups were
compared. Results: 113 cases in the treatment group were cured by traditional Chinese
medicine Jianpi Qushi powder combined with standard anti HP quadruple therapy,
and the cure rate was 92.62%. 84 cases in the control group were cured by
standard anti HP quadruple therapy, and the cure rate was 83.17%, χ2 = 4.7955, P = 0.0285, the
difference was statistically significant (P < 0.05). Conclusion: Traditional
Chinese medicine Jianpi Qushi powder combined with standard anti HP quadruple
therapy in the treatment of HP infectious gastritis with spleen deficiency and
dampness stagnation is one of the best treatment schemes for HP infection. The
results of this study achieve the best clinical treatment effect, and provide a
more valuable and reliable method for the treatment of gastropathy in clinical
internal medicine, which is worthy of popularization and application.
References
[1]
Cui, C.C., Li, C.F. and Zhang, B. (2017) Research Status and Progress of Treatment Schemes for Helicobacter pylori Infection. Journal of Jilin University (Medical Edition), 43, 1287-1290.
[2]
Technische Universität München, max-planck-gesellschaft zur förderung der wissenschaften e.v. Helicobacter pylori Vaccines: World Patent Organization, WO2017102779(A1). 2017-06-22.
[3]
Boltin, D. and Shirin, H. (2019) Summary of the Israel Gastroenterology Association (Iga) Guidelines for the Management and Treatment of Helicobacter Pylori in 2019. Harefuah, 158, 398-403.
[4]
Univ nat taiwa. Composition for the Prevention and the Treatment of Helicobacter pylori Infection: US, US2010298244(A1). 2010-11-25.
[5]
Shiota, S. and Yamaoka, Y. (2014) Strategy for the Treatment of Helicobacter pylori Infection. Current Pharmaceutical Design, 20, 4489-4500. https://doi.org/10.2174/13816128113196660731
[6]
Compagnie gervais danone. Streptococcus Thermophilus Strains for Treating Helicobacter pylori Infection: World Patent Organization, WO2014064488(A1). 2014-05-01.
[7]
Shionogi & Co Ltd. Vaccine Composition for Infection of Helicobacter pylori: Japan, JP2000083671. 2000-03-28.
[8]
Harris, A. (2001) Treatment of Helicobacter pylori. World Journal of Gastroenterology (English Version), 7, 303-307. https://doi.org/10.3748/wjg.v7.i3.303
Karolinska inst innovations abjonsson ann-bethwehelie rahm. Compounds, Medicaments and Methods of Treatment for Helicobacter pylori Infection. World Patent Organization, WO2011139226(A1). 2011-11-10.
[11]
Kimura ken (jp), kaken pharma co Ltd (JP). Composition for the Treatment of Helicobacter pylori Infection: US, US5618564. 1997-04-08.
[12]
Go, M.F. and Fennerty, M.B. (1998) Treatment of Helicobacter pylori Infection. Current Opinion in Gastroenterology, 14, 64-69. https://doi.org/10.1097/00001574-199801000-00012
[13]
Coton, T., Debonne, J.-M., Guisset, M., et al. (1997) L’infection a Helicobacter pylori dans les pays en developpement. Medecine Tropicale, 57, 77-82.
[14]
Academia Sinica. Compositions and Assays for Treatment and Diagnosis of Helicobacter pylori Infection and Conditions: US, US8785402(B2). 2014-07-22.
[15]
Chey, W.D., Leontiadis, G.I., Howden, C.W., et al. (2017) ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. The American Journal of Gastroenterology, 112, 212-239. https://doi.org/10.1038/ajg.2016.563
[16]
O’Connor, A., O’Morain, C.A. and Ford, A.C. (2017) Population Screening and Treatment of Helicobacter pylori Infection. Nature Reviews. Gastroenterology & Hepatology, 14, 230-240. https://doi.org/10.1038/nrgastro.2016.195
[17]
RedHill Biopharma Ltd. Pharmaceutical Compositions for the Treatment of Helicobacter pylori: US, US2017189341(A1). 2017-07-06.
[18]
Tongtawee, T. and Wattanawongdon Wareeporn, S. (2019) Effects of Periodontal Therapy on Eradication and Recurrence of Helicobacter pylori Infection after Successful Treatment. Journal of International Medical Research, 47, 875-883. https://doi.org/10.1177/0300060518816158
[19]
Dong, H., Jin, S.-L. and Miao, D.-L. (2017) Interpretation of ACG Clinical Guideline: Treatment of Helicobacter pylori Infection (Version 2017). International Journal of Translational Medicine (English Version), 5, 160-166.
[20]
Ranjbar, R., Behzadi, P. and Farshad, S. (2017) Advances in Diagnosis and Treatment of Helicobacter pylori Infection. Acta Microbiologica et Immunologica Hungarica, 64, 273-292. https://doi.org/10.1177/0300060518816158
[21]
Okuda, M., Kikuchi, S., Mabe, K., et al. (2017) Nationwide Survey of Helicobacter pylori Treatment for Children and Adolescents in Japan. Pediatrics International, 59, 57-61. https://doi.org/10.1111/ped.13038
[22]
Zhang, Y., Sun, H., Zhao, H.L., et al. (2017) Early Apoptosis of Monocytes Induced by Helicobacter pylori Infection through Multiple Pathways. Developmental and Comparative Immunology: Ontogeny, Phylogeny, Aging, 73, 46-51. https://doi.org/10.1016/j.dci.2017.03.010
[23]
Ribichini, D., Castelli, V., Pasquali, R., et al. (2017) Tablet and Oral Liquid L-Thyroxine Formulation in the Treatment of Na < Ve Hypothyroid Patients with Helicobacter pylori Infection. Endocrine, 57, 394-401. https://doi.org/10.1007/s12020-016-1167-3
[24]
Karolinska Inst Innovations A. Compounds, Medicaments and Methods of Treatment for Helicobacter pylori Infection: European Patent Office, EP2566498(A1). 2013-03-13.
[25]
Ma, H., Gao, H., Huang, Y.B., et al. (2017) Therapeutic Effect of Compound Lactobacillus acidophilus Combined with Conventional Quadruple Therapy on Peptic Ulcer Infected by Helicobacter pylori. Chinese Journal of Nosocomial Infection, 27, 2932-2934, 2946.
